Overview

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

A phase II randomised, open label study of pre-operative endocrine therapy with & without prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+) human epidermal receptor 2 negative (HER2-) breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

St. Vincent's Hospital-Manhattan

Treatments:

Hormones
Letrozole
Progesterone
Tamoxifen